‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data

Live updates

1. 2h ago

   Merck Unruffled by Cancer Vaccine Data Leak Ahead of ESMO

   A high-profile data leak ahead of the European Society for Medical Oncology congress temporarily disrupted markets for Merck and Moderna, but executives and financial analysts remain unruffled. The partners revealed detailed results from the Phase 3 INTerpath-001 trial evaluating their personalized mRNA cancer vaccine for melanoma. Initial stock selloffs reversed as analysts warmed to the trial data following the official presentation in Madrid. The therapy successfully cut the risk of melanoma recurrence or death by 42% in the Phase 3 trial.

   Why it matters

   Merck and Moderna prepared for major headlines in Madrid for the headlining reveal of their personalized cancer vaccine data. However, the details leaked online ahead of the official presentation, sparking a stock selloff and investor whiplash. Executives dismissed the early disclosure as unfortunate while maintaining that the premature leak does not establish efficacy, safety, or regulatory progress on its own.

   What is confirmed

   • Data for Merck and Moderna's personalized cancer vaccine leaked online ahead of the European Society for Medical Oncology congress in Madrid.
   • The Phase 3 INTerpath-001 trial data showed the therapy cuts the risk of melanoma recurrence or death by 42%.
   • A Merck executive described the data leak as unfortunate but stated that it is what it is.
   • Moderna shares plunged following the leak of the cancer vaccine data.

   What to watch next

   • Further regulatory progress and safety updates from Merck and Moderna regarding the personalized mRNA cancer vaccine.
   • Broader industry efforts to expand the impact of the cancer vaccine following its first success.
   Sources used for this update (15)

   1. www.ign.com — IGN's Top Reviewed Movies of 2026 So Far
   2. CNBC — Moderna shares plunge after leak of cancer vaccine data despite positive results
   3. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
   4. Yahoo Finance — Moderna stock extends losses as investors digest melanoma vaccine trial data
   5. WSJ — Moderna Investors Should Brace for More Whiplash
   6. Fierce Biotech — ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
   7. STAT — The ESMO presentation everyone’s been waiting for
   8. Yahoo Finance — Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
   9. STAT — After a cancer vaccine’s first success, the race is on to expand the impact
   10. ABC News - Breaking News, Latest News and Videos — Breakthrough cancer vaccine reduces melanoma from returning by 42%, data shows
   11. www.biotech-now.co.uk — 'It is what it is': Merck exec unruffled by 'unfortunate ...
   12. global.svn.com — Merck Executive Unruffled by Cancer Vaccine Data Leak
   confidence 90%